日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia

一项针对人组织因子途径抑制剂的marstacimab治疗血友病的1b/2期临床研究

Mahlangu, Johnny N; Lamas, Jose Luis; Morales, Juan Cristobal; Malan, Daniel R; Šalek, Silva Zupančić; Wang, Michael; Boggio, Lisa N; Hegemann, Inga; Mital, Andrzej; Cardinal, Matthew; Zhu, Tong; Sun, Pengling; Arkin, Steven

Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa

南非未接受治疗的丙型肝炎病毒基因型 5 的变异性

Tshegofatso K Maunye, Maemu P Gededzha, Jason T Blackard, Johnny N Rakgole, Selokela G Selabe

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies

使用重组凝血因子VIII Fc和凝血因子IX Fc治疗血友病手术:来自3期关键性研究的安全性和有效性数据

Chowdary, Pratima; Holmström, Margareta; Mahlangu, Johnny N; Ozelo, Margaret C; Pabinger, Ingrid; Pasi, K John; Ragni, Margaret V; Shapiro, Amy; Barnowski, Chris; Lethagen, Stefan

Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis

Visabron 的合成和药理学表征,一种用于治疗多发性硬化症的 α4β1 (VLA-4)/α9β1 整合素的骨架环肽双重拮抗剂

Chaim Gilon, Michal Klazas, Adi Lahiani, Adi Schumacher-Klinger, Shira Merzbach, Johnny N Naoum, Haim Ovadia, Limor Rubin, Susan Cornell-Kennon, Erik M Schaefer, Jehoshua Katzhendler, Cezary Marcinkiewicz, Amnon Hoffman, Philip Lazarovici

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database

将血友病死亡率框架应用于艾美赛珠单抗全球安全性数据库

Peyvandi, Flora; Mahlangu, Johnny N; Pipe, Steven W; Hay, Charles R M; Pierce, Glenn F; Kuebler, Peter; Kruse-Jarres, Rebecca; Shima, Midori

Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database

建立评估先天性血友病A患者死亡率的框架及其在不良事件报告数据库中的应用

Pipe, Steven W; Kruse-Jarres, Rebecca; Mahlangu, Johnny N; Pierce, Glenn F; Peyvandi, Flora; Kuebler, Peter; De Ford, Christian; Sanabria, Fabián; Ko, Richard H; Chang, Tiffany; Hay, Charles R M

A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH

国际血栓与止血学会(ISTH)科学标准委员会发布了一项新的血友病携带者命名法,旨在定义女性和女孩的血友病。

van Galen, Karin P M; d'Oiron, Roseline; James, Paula; Abdul-Kadir, Rezan; Kouides, Peter A; Kulkarni, Roshni; Mahlangu, Johnny N; Othman, Maha; Peyvandi, Flora; Rotellini, Dawn; Winikoff, Rochelle; Sidonio, Robert F

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies

A型血友病患者对艾美赛珠单抗治疗的偏好与既往因子治疗的偏好:HAVEN 3和HAVEN 4研究的结果

Parnes, Aric; Mahlangu, Johnny N; Pipe, Steven W; Paz-Priel, Ido; Lehle, Michaela; Trask, Peter C; Jiménez-Yuste, Víctor

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors

静脉或皮下注射血友病药物满意度问卷的开发和测试,以及针对无FVIII抑制剂的A型血友病患者使用emicizumab预防治疗的3期HAVEN 3研究结果

Kempton, Christine; Trask, Peter; Parnes, Aric; Niggli, Markus; Campinha-Bacote, Avrita; U Callaghan, Michael; O'Connell, Niamh; Paz-Priel, Ido; Mahlangu, Johnny N

Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management

抗组织因子通路抑制剂在血友病治疗中的研发进展

Mahlangu, Johnny N